BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

28 related articles for article (PubMed ID: 31570483)

  • 1. Clinicopathological and Molecular Characteristics Promoting PD-L1 Expression in Early-stage Lung Adenocarcinoma and Squamous Cell Carcinoma.
    Ito A; Tarukawa T; Suzuki Y; Sakaguchi T; Ito K; Fujiwara K; Nishii Y; Taguchi O; Yasui H; Takao M; Hataji O
    Anticancer Res; 2023 Nov; 43(11):5197-5204. PubMed ID: 37909981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approaches to Tumor Classification in Pulmonary Sarcomatoid Carcinoma.
    Baldovini C; Rossi G; Ciarrocchi A
    Lung Cancer (Auckl); 2019; 10():131-149. PubMed ID: 31824199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary pleomorphic carcinoma treated with PD-1 inhibitor: Two case reports.
    Jiang T; Wang H; Xue F; Wu X; Ni M; Wang Y; Chen N; Zhang Y; Zhang G; Fu J; Liu X; Wu Q
    Thorac Cancer; 2023 Nov; 14(32):3240-3244. PubMed ID: 37779217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report.
    Chen Y; Zhang H; Shi J; Wang T
    Onco Targets Ther; 2020; 13():12471-12476. PubMed ID: 33299330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary pleomorphic carcinoma presenting as undifferentiated non-small cell carcinoma with giant cells: A case report and review of literature.
    Jeong JH; Seo HJ; Yoon SH; Hong R
    Respir Med Case Rep; 2020; 31():101225. PubMed ID: 33005565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High programmed death ligand 1 expression in carcinomatous components predicts a poor prognosis in pulmonary pleomorphic carcinoma.
    Noguchi M; Menju T; Nakajima N; Yoshizawa A; Ohsumi A; Nakajima D; Hamaji M; Haga H; Date H
    Surg Today; 2022 Jul; 52(7):1090-1095. PubMed ID: 35041089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
    Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS
    J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological Features, Surgical Outcomes, Oncogenic Status and PD-L1 Expression of Pulmonary Pleomorphic Carcinoma.
    Nakanishi K; Sakakura N; Matsui T; Ueno H; Nakada T; Oya Y; Shimizu J; Hida T; Hosoda W; Kuroda H
    Anticancer Res; 2019 Oct; 39(10):5789-5795. PubMed ID: 31570483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 Expression Status Predicting Survival in Pulmonary Pleomorphic Carcinoma.
    Hisakane K; Seike M; Sugano T; Matsuda K; Kunugi S; Nakamichi S; Matsumoto M; Miyanaga A; Noro R; Minegishi Y; Kubota K; Gemma A
    Anticancer Res; 2021 May; 41(5):2501-2509. PubMed ID: 33952478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung.
    Imanishi N; Hirai A; Yoneda K; Shimajiri S; Kuwata T; Tashima Y; Takeuchi M; Iwai Y; Ichiki Y; Tanaka F
    J Surg Oncol; 2018 Jun; 117(7):1563-1569. PubMed ID: 29601633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
    Takada K; Okamoto T; Shoji F; Shimokawa M; Akamine T; Takamori S; Katsura M; Suzuki Y; Fujishita T; Toyokawa G; Morodomi Y; Okano S; Oda Y; Maehara Y
    J Thorac Oncol; 2016 Nov; 11(11):1879-1890. PubMed ID: 27346415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Significance of Tumor Immunity in Surgically Resected Pulmonary Pleomorphic Carcinoma.
    Kaira K; Shimizu K; Endoh H; Imaizumi K; Kamiyoshihara M; Sugano M; Kawashima O; Tanaka S; Fujita A; Imai H; Kogure Y; Oyama T; Asao T; Shirabe K
    Anticancer Res; 2020 Jan; 40(1):261-269. PubMed ID: 31892575
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.